Publications Scientifiques
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment
A French nationwide cohort study (GCO-002 CACOVID-19) in the European Journal of Cancer (December 2020).
Rx Ponder Cllinical Trial Design Swog S1007 : adjuvant trial randomized ER+ patients who had a Recurrence Score < 25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy.
Virtual San Antonio Breast Cancer Symposium December 10, 2020.
150O_PR – Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients
with HER2-positive metastatic breast cancer (MBC)
The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG) (ID 547) Esmo 2019 Berlin Germany
The CTS5 risk score overestimates the risk of late distant recurrences in high risk patients with HR positive breast cancer : a validation study using the TEAM and IDEAL trial
Iris Noordhoek, Erik J blok, Elma M-Klein Kranenbarg, Jean Michel Vannetzel. This work has been presented as an oral presentation at the ESMO Breast Cancer Conference on May
4th, 2019 in Berlin, Germany.
The Oncotype DX Breast Recurrence Score® test acknowledged with strong recommendation in the updated ASCO Guidelines 2019
Phare study :6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE)
4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Lancet 6 juin 2019.
Effectiveness and safety of Nivolumab in the treatment of lung cancer patients in France
Updated survival and subgroup analyses from the
real- world EVIDENS study. : Barlesi F.1, Dixmier A.2, Debieuvre D.3, Raspaud C. Esmo 2019
Role of deficient DNA Mismatch repair status in patients traited with stage III colon cancer treated with Folfox adjuvant chemotherapy.
A pooled analysis from 2 randomized clinical trials. Aziz Z. ; Qian S ; Taieb J et al. Jama oncol. 2018 ; 4(3) :379-383.
Etude Ago-Ovar 2.21
A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs carboplatin /pegyloted liposomal doxorubicin
/bevacizumab in patients whit platinun-sensitive recurrent ovarian cancer. Esmo 2018
UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and
then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.
Eur J Cancer. 2018 Sep 26;103:184-194.doi:10.1016/j.ejca.2018.06.025.
[Epub ahead of print Campone M &al.
A French observational study of Nivolumab-treated lung cancer patients
in a real – world setting
Initial results on 1394 avanced non small cell
lung cancer patients. Evidens trial.
Abst. 1469P ; Esmo , 20 octob.2018.
PHARE : study randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer
Swog S1007 : adjuvant trial randomized ER+ patients who had a Recurrence Score < 25 and 15 décembre 2018 en session plénière au San Antonio Breast Cancer Symposium (SABCS)
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter
H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix
LY, van de Velde CJH. Lancet Oncol. 2017 Sep;18(9):1211-1220. doi: 10.1016/S1470-
2045(17)30419-9. Epub 2017 Jul 18
Correlation betwen Oncotype DX recurrence score and classical risk factors in early
breast cancer.
Abstract 12011 .Asco Journal 2017.18.
DPYD genotyping to predict adverse events following treatment with fluorouracil-
based adjuvant chemotherapy in patients with stage III colon cancer
A secondary analysis of the PETACC 8 randomized clinical trial.
Boige V, Vincent M, Alexandre P
JAMA Oncol 2016 Jan 21. doi :10,1001
Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab
A post hoc analysis of the PETACC-8 trial.
Taieb J, ZaananA, Le Malicot K. JAMA Oncol 2016 jan 15/14.1-11
Primary analysis of the Eortc 1004/BIG 3-04 Mindact study
A prospective, randomized study evaluating the clinical utility of the 70-gene signature (mammaPrint) combined with common clinical pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.
M.Piccart, E.Rutgers S.Delage ; AACR, April 28, 2016
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclosphosphamide in node-positive breast cancer.
CRIG-005 randomized trial. Mcacket JR, Pienkowski T, Crown J
AnnOncol (2016 ) V 27(6) :1041-1047 doi : 10.1093/annonc/mdw 098.
Concomitant ou séquentiel pour le trastuzumab adjuvant
Etude combinée de PHARE et SIGNAL : Esmo 2016 PivotX et al ; abstr 1440
Enquête PONDx en France
Enquête d’utilisation du test Oncotype DX en
practique clinique courante. Courtit E, Bourgeois H, Laharie H, Vannetzel JM, Bonichon-Lamichhane N
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16)
A randomised, multicentre, open-label phase 3 trial.
The Lancet Oncology Volume 17, No. 6, p747–756, June 2016 : Carrie C, Hasbini A,
Delaroche G
Interest of short androgen deprivation therapy (ADT) combined with radiotherapy (RT) as salvage for biological relapse (BR) after radical prostatectomy (RP) results of GetuG-AFU 16 phase III randomized trial
asco 2015 abst 5006
Pepita Etude prospective de cohorte évaluant l’efficacité et la tolérance d’un traitement de 2ed ligne par Tarceva chez de patients atteints d’un cancer bronchique non à petites cellules(CBNPC) de type épidermoïde avancé ou métastatique
Janvier-Février 2015 : 19 congres de pneumologie française
Erlotinib in 2nd line in advanced squamous : N abstract WCLC 2015 (total 490 words for 500 words allowed SCLS
Final results of the PEPITA cohort : A.Vergnenègre, O.Molinier, I.Monnet, Paris-France
Epidermal growth factor receptor (EGFR) pathway biomarkers in the randomized Phase III trial of Erlotinib versus Observation in Ovarian cancer patients with no evidence of disease progression after first-line platinum-based chemotherapy
Despierre E, Vergote I, Anderson R.
Targeted Oncology : Dec 2015, volume 10,issue 4
Final Analysis :Ten year follow-up of BCIRG 006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AT> T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC >TH) with docetaxel, carboplatin and trastuzumab TCH) in HER2+ early breast cancer
Slamon D, EiermannW, Robert N, Giermek J, on behallf of the BCIRG – 006 investigators SABC 8-12 Decembre 2015
Multicentre randomised phase II trial of gemcitabine+ platinum, with or without trastuzumab in advanced or metastatic urothelial carcinoma overexpressing HER2
Eur J Cancer 2015 Jan 15 ; 51(1)45-54
S.Oudart, S.Culine, Y.Vano
Minimal impact of adjuvant exemstane or tamoxifen treatment on mammographic breast density in postmenospausal breast cancer patients
A Dutch TEAM trial analysis.
Acta Oncol, 2015 Mar ; 54(3) : 349-60
Interest of short androgen deprivation therapy (ADT) combined with radiotherapy (RT) as salvage for biological relapse (BR) after radical prostatectomy (RP) results of GetuG-AFU 16 phase III randomized trial
asco 2015 abst 5006
Pepita Etude prospective de cohorte évaluant l’efficacité et la tolérance d’un traitement de 2ed ligne par Tarceva chez de patients atteints d’un cancer bronchique non à petites cellules(CBNPC) de type épidermoïde avancé ou métastatique
Janvier-Février 2015 : 19 congres de pneumologie française
Erlotinib in 2nd line in advanced squamous : N abstract WCLC 2015 (total 490 words for 500 words allowed SCLS
Final results of the PEPITA cohort : A.Vergnenègre, O.Molinier, I.Monnet, Paris-France
Epidermal growth factor receptor (EGFR) pathway biomarkers in the randomized Phase III trial of Erlotinib versus Observation in Ovarian cancer patients with no evidence of disease progression after first-line platinum-based chemotherapy
Despierre E, Vergote I, Anderson R.
Targeted Oncology : Dec 2015, volume 10,issue 4
Phase III study of Vinflunine plus Gemcitabine versus Paclitaxel plus Gemcitabine in first line treatment of anthracycline pretreated advanced breast cancer
Study Victoria: Abstract Asco 2014
Nanobitic sélectionnée pour presenter les donnes de l’étude de NBTXR3 lors de la 50 ème conférence Asco
Chicago june 2- 2014 poster
Phase II study of cetuximab pemetrexed, cisplatin and concurrent radiotherapie in patients with locally advanced, unresectable stage III, non-squamous non-small cell lung cancer (NSCLC)
Results of the IFCT-0803 trial ;abstract discussion session S405, Asco June 1 – Chicago 2014
Hormonothérapie des cancers du sein. Quoi de neuf ?
LA LETTRE DU CHIRURGIEN : GENESIS — N° 181
Octobre/Novembre 2014
JM Vannetzel, JF Llory, E Sebban.
Second line therapy in elderly patients with advanced no small cell lung cancer
Quoix E, Westeel V, Moreau L.
European Respiratory Journal 2014, 43 : 240-249 2015
Oxaliplatin,fluorouracil and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8)
An open label, randomised phase trial.
Taieb J, Tabernero J, Subtil F
Pettac -8 Study investiagtors. Lancet Oncol. 2014 jul ;15(8) :862-73.
Prognostic value of KRAS mutations in stage III colon cancer
Post-hoc analysis of the PETTAC 8 phase III trial dataset.
Blons H, Emile JF, Le Malicot K. Ann Oncol. 2014 ;Dec ;25(12) 2378-85
Phase III study of Vinflunine plus Gemcitabine versus Paclitaxel plus Gemcitabine in first line treatment of anthracycline pretreated advanced breast cancer
Study Victoria: Abstract Asco 2014
Nanobitic sélectionnée pour presenter les donnes de l’étude de NBTXR3 lors de la 50 ème conférence Asco
Chicago june 2- 2014 poster
Phase II study of cetuximab pemetrexed, cisplatin and concurrent radiotherapie in patients with locally advanced, unresectable stage III, non-squamous non-small cell lung cancer (NSCLC)
Results of the IFCT-0803 trial ;abstract discussion session S405, Asco June 1 – Chicago 2014
Hormonothérapie des cancers du sein. Quoi de neuf ?
LA LETTRE DU CHIRURGIEN : GENESIS — N° 181
Octobre/Novembre 2014
Second line therapy in elderly patients with advanced no small cell lung cancer
Quoix E, Westeel V, Moreau L.
European Respiratory Journal 2014, 43 : 240-249 2015
Oxaliplatin,fluorouracil and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8)
An open label, randomised phase trial.
Taieb J, Tabernero J, Subtil F
Pettac -8 Study investiagtors. Lancet Oncol. 2014 jul ;15(8) :862-73.
Prognostic value of KRAS mutations in stage III colon cancer
Post-hoc analysis of the PETTAC 8 phase III trial dataset.
Blons H, Emile JF, Le Malicot K. Ann Onc
